EXTON, PA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Following this week’s European Commission approval of Roche/Genentech’s Gazyvaro (obinutuzumab) for the treatment of lupus nephritis (LN), Spherix Global Insights’ latest RealTime Dynamix™: Lupus Nephritis (EU) study indicates that the newly approved biologic is positioned to drive significant therapeutic shifts across the EU5 LN market. Even prior to approval, rheumatologists and nephrologists across France, Germany, Italy, Spain, and the UK (n=252) demonstrated strong enthusiasm and readiness to integrate Gazyvaro, and momentum is now expected to accelerate with formal authorization.
Across specialties, early sentiment points to Gazyvaro’s potential to serve as a new biologic anchor in LN treatment. Clinicians report reassessing long-standing sequencing paradigms and preparing to incorporate a mechanism of action now formally validated for this population. This reflects more than simple interest: it signals an inflection point in how European specialists conceptualize early and sustained control of LN, particularly as emphasis on rapid remission and steroid minimization continues to grow. Off-label users of Gazyvaro have already expressed notably high satisfaction, reinforcing confidence in the biologic’s expected real-world performance as it becomes broadly accessible.
More than half of participating specialists view Gazyvaro as a substantial advance over currently available LN therapies, reinforcing expectations that it will elevate treatment standards rather than simply broaden choice. Nephrologists and rheumatologists anticipate the therapy will overtake current off-label rituximab usage within six months, while also drawing share from GSK’s Benlysta. Nearly 30% of Class III and IV ± V LN patients are considered appropriate candidates, with German specialists anticipating the highest eligibility rates.
Critically, Gazyvaro’s launch is expected to expand the overall LN biologic market, not merely redistribute share. Nephrologists and rheumatologists project broader biologic uptake as the therapy becomes available, reflecting rising clinical confidence in advanced systemics and a shifting preference toward earlier, more intensive intervention to achieve durable renal control. These early projections highlight Gazyvaro’s potential to redefine the scale and composition of LN treatment across Europe.
While clinicians remain divided on immediate placement, split between early-line induction use and second-line positioning, this reflects variation in readiness rather than doubt. Many expect Gazyvaro’s role to broaden over time as real-world experience accumulates and access clarity improves. Specialists emphasizing early-line use consistently cite strong efficacy expectations, steroid-sparing potential, and convenience of dosing, while those opting for second-line initiation highlight the desire for experience-building and country-specific reimbursement considerations.
Even with multiple approved advanced systemics, unmet needs in LN remain substantial. Only about half of patients treated with advanced therapies achieve adequate disease control, underscoring persistent gaps in remission durability, flare reduction, and long-term renal protection. Expectations for Gazyvaro’s impact are rooted not only in competitive positioning but in the belief that a validated, differentiated B-cell therapy may help address these ongoing challenges.
These insights, and their implications for manufacturers navigating a fast-evolving LN landscape, are detailed in RealTime Dynamix™: Lupus Nephritis (EU) Q4 2025. In 2026, Spherix will expand its European LN portfolio to twice-annual tracking and will also publish a large-scale EU5 patient audit, Patient Chart Dynamix™: SLE/LN (EU) study, providing deeper real-world visibility into patient journeys and treatment outcomes.
About RealTime Dynamix™
RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts.
About Patient Chart Dynamix™
Patient Chart Dynamix™ is an independent service that includes robust patient chart audits and integrated specialist surveys fielded biannually. This research provides an in-depth, real-world view of treatment practices by combining verified patient data with attitudinal insights from physicians. The series highlights clinical decision-making, treatment sequencing, and outcomes for targeted patient populations across key therapeutic areas.
About Spherix Global Insights
Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.
The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.
As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.
To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com
NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.
